PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
186.72%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
201.62%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
201.62%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
4.85%
Interest expense growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
EBITDA decline while AGEN shows 33.88% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
Operating income decline while AGEN shows 30.25% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
201.62%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
128.59%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
-128.59%
Net income decline while AGEN shows 148.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-127.78%
EPS decline while AGEN shows 147.47% growth. Joel Greenblatt would examine position.
-127.78%
Diluted EPS decline while AGEN shows 147.47% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.